TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy

Loss of p53 promotes vascular endothelial growth factor (VEGF)-A up-regulation and the angiogenic potential of cancer cells. We investigated TP53 somatic mutations in 110 primary gastric adenocarcinomas of two retrospective metastatic series including 48 patients treated with second-line Ramucirumab...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Autores principales: Graziano, Francesco, Fischer, Nicholas W., Bagaloni, Irene, Di Bartolomeo, Maria, Lonardi, Sara, Vincenzi, Bruno, Perrone, Giuseppe, Fornaro, Lorenzo, Ongaro, Elena, Aprile, Giuseppe, Bisonni, Renato, Prisciandaro, Michele, Malkin, David, Gariépy, Jean, Fassan, Matteo, Loupakis, Fotios, Sarti, Donatella, Del Prete, Michela, Catalano, Vincenzo, Alessandroni, Paolo, Magnani, Mauro, Ruzzo, Annamaria
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7465166/
https://ncbi.nlm.nih.gov/pubmed/32722340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082049
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares